


## Data Sheet

<b>Product Name:</b>	Atuliflapon
<b>Cat. No.:</b>	CS-0090377
<b>CAS No.:</b>	2041075-86-7
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>26</sub> N <sub>6</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	446.50
<b>Target:</b>	FLAP
<b>Pathway:</b>	Immunology/Inflammation
<b>Solubility:</b>	DMSO : 125 mg/mL (279.96 mM; Need ultrasonic)



### BIOLOGICAL ACTIVITY:

Atuliflapon (AZD5718) is an orally active inhibitor of **FLAP (5-Lipoxygenase activating protein)**, with an **IC<sub>50</sub>** of 2 nM. Atuliflapon is used in the study for coronary artery disease<sup>[1]</sup>. IC<sub>50</sub> & Target:IC<sub>50</sub>: 2 nM (FLAP)<sup>[1]</sup>.

*In Vitro*: Atuliflapon demonstrates a dose dependent and greater than 90% suppression of leukotriene production over 24 h<sup>[1]</sup>.

Atuliflapon exhibits an IC<sub>50</sub> of 39 nM for LTB<sub>4</sub><sup>[1]</sup>. *In Vivo*: Atuliflapon exhibits t<sub>1/2</sub> of 0.45 h and 2.1 h in rat and dog by iv injection, respectively<sup>[1]</sup>.

Atuliflapon shows no inhibition of 5-LO pathway activity in rodent blood<sup>[1]</sup>.

### References:

[1]. Daniel Pettersen, et al. Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease. J Med Chem. 2019 May 9;62(9):4312-4324.

### CAIndexNames:

Cyclohexanecarboxamide, 2-[4-(5-methyl-1H-pyrazol-3-yl)benzoyl]-N-(4,5,6,7-tetrahydro-4-oxopyrazolo[1,5-a]pyrazin-3-yl)-, (1R,2R)-

### SMILES:

O=C([C@H]1[C@H](C(C2=CC=C(C3=NNC(C)=C3)C=C2)=O)CCCC1)NC4=C(N(N=C4)CCN5)C5=O

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA